Merck partners with small UK biotech to drug fibroblasts for fibrosis, I&I...
As Merck builds out its immunology research lab in London, it’s partnering with a local biotech startup that has remained relatively quiet since its seed round in 2021. The pharma giant said Tuesday...
View ArticleClik here to view.
Astellas places new bet on gene therapy in $50M upfront deal with London's...
As it works to rebuild from an earlier gene therapy setback, Astellas is doubling down on the one-and-done modality in a new deal with a London-based startup already in the clinic. Astellas said...
View ArticleClik here to view.
Sage faces third Phase 2 fail in six months as dalzanemdor misses goal in...
Sage Therapeutics is reeling from another mid-stage setback as its investigational medicine dalzanemdor has missed the mark in a Phase 2 mild cognitive impairment trial. The drug, an NMDA receptor...
View ArticleClik here to view.
Exclusive: Lilly backs a16z-funded Arda Therapeutics' $43M Series A to take...
A three-year-old startup based on decades of research in cell depletion is betting that some of the hottest tools in oncology may work even better in other diseases. Arda Therapeutics has raised a $43...
View ArticleOrasis snags $78M to launch presbyopia eye drops more than a year after FDA...
Last October was an FDA approval. This October is a $68 million fundraising round. Next year, maybe a drug launch. Orasis Pharmaceuticals announced a Series D round on Tuesday, plus another $10 million...
View ArticleClik here to view.
Biogen to seek approval for high-dose Spinraza after unveiling new data
Nearly eight years after securing a historic first approval for a spinal muscular atrophy drug, Biogen is seeking to launch a new dosing regimen of Spinraza. Clinical trial data unveiled on Tuesday...
View ArticleScholar Rock aims to raise $275M; Vincerx to reshuffle pipeline focus
Plus, news about Vicore: Scholar Rock seeks $275M in stock sale: After announcing the success of a pivotal clinical trial for its muscle-targeted spinal muscular atrophy treatment, Scholar Rock’s...
View ArticleClik here to view.
Black Diamond cuts workforce, prioritizes lung cancer drug
Black Diamond Therapeutics is cutting an unspecified number of workers, including several executives, and making changes to its pipeline in an effort to extend its cash runway. Fang Ni As part of the...
View ArticlePfizer's former top executives pitched changes to board as part of activist's...
Pfizer’s former CEO and CFO relayed proposals from activist investor Starboard Value to several members of the company’s board on Sunday, according to a source familiar with the conversations, as part...
View ArticleExclusive: A small San Diego biotech wants to change how Parkinson’s disease...
A protein called alpha-synuclein that accumulates and ravages the brains of some people with Parkinson’s disease is the target of several experimental drugs. Until recently, the only way to detect it...
View ArticleJohn Maraganore's RNAi biotech City Therapeutics debuts with $135M Series A
City Therapeutics has launched with $135 million and Alnylam’s former CEO leading the charge as it develops a pipeline of next-generation RNAi therapies that could act on tissues apart from the liver,...
View ArticleCompounding pharmacy group sues FDA for ending Eli Lilly's GLP-1 drug shortage
A trade group for large compounding pharmacies sued the FDA over its move to take Eli Lilly’s blockbuster GLP-1 drug off its shortage list, hamstringing compounders’ ability to create their own,...
View ArticleJim Wilson secures $100M for global approach aimed at reviving gene therapy...
A gene therapy pioneer thinks he has a solution to the field’s struggle to commercialize breakthrough cures: Go global. Jim Wilson’s Philadelphia-based company GemmaBio on Tuesday announced up to $100...
View ArticleFDA again raises doubts on Stealth's ultra-rare disease drug ahead of adcomm
Data submitted to the FDA by Stealth BioTherapeutics for its ultra-rare disease drug likely aren’t sufficient for an approval or even an accelerated approval, agency staff said in briefing documents...
View ArticlePfizer culls RSV treatment from ReViral acquisition
Pfizer has terminated development of its RSV treatment candidate sisunatovir, a viral inhibitor picked up in its up to $525 million acquisition of ReViral in 2022. The New York drug company — which is...
View ArticleClik here to view.
GSK's RSV vaccine Arexvy shows long-term protection in Phase 3 trial
GSK said a dose of its RSV vaccine protected against illness over three years, according to new data presented at the CHEST 2024 Annual Meeting. In the Phase 3 trial, called AReSVi-006, a dose of...
View ArticleClik here to view.
Purespring nabs $105M to take gene therapy into the clinic as IgAN field matures
Purespring Therapeutics has reeled in £80 million ($105 million) to test two gene therapies in humans. The Sofinnova Partners-led Series B, disclosed Wednesday morning, will carry the London startup...
View ArticleKevin Tang's Concentra swoops in on another struggling biotech, offering to...
Concentra Biosciences, a shell company from Tang Capital, wants to buy another biotech that has found itself in a bind. Kevin Tang’s shop told Kezar Life Sciences’ board on Tuesday that it is willing...
View ArticleBasecamp raises $60M to travel the globe and fill AI data gaps, signs deal...
London-based startup Basecamp Research has closed a $60 million Series B round that will help expand its genomic database and what it sees as gaps in biological information that will be needed to build...
View ArticleAI biotech insitro partners with Lilly on metabolic disease drugs
If all goes according to plan, insitro could finally start testing its first drug in clinical trials in 2026, eight years after Daphne Koller founded the AI-powered biotech. To get there, it’s teaming...
View Article